Tirzepatide, along with several similar types of drugs taken for diabetes, went into shortage last year as success stories posted on social media fueled runaway demand for their weight loss benefits
A clinician should also review other health conditions, medications, and pregnancy considerations before treatment
Another trial, SURMOUNT-2, investigated the effect of Tirzepatide compared to semaglutide (another GLP-1 receptor agonist) in obese individuals with type 2 diabetes
This suggests that GLP-1s could be a promising therapeutic treatment against brain inflammation in conditions like Alzheimers, Parkinsons, ALS, and multiple sclerosis
It may also be considered for patients who have tried semaglutide and did not reach their treatment goals, although switching should only happen with medical guidance